Read + Share
Brightling CE, Caminati M, Llanos JP, Caveney S, et al. Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up
from the 2-year DESTINATION study. Ann Allergy Asthma Immunol 2024;133:310-317.
PMID: 38697286
|
 |
|
Brightling CE, Caminati M, Llanos JP, Caveney S, et al. Biomarkers and clinical outcomes after tezepelumab cessation: Extended follow-up
from the 2-year DESTINATION study. Ann Allergy Asthma Immunol 2024;133:310-317.
PMID: 38697286
|
|
|
|